A detailed history of Jpmorgan Chase & CO transactions in Lantern Pharma Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 128 shares of LTRN stock, worth $563. This represents 0.0% of its overall portfolio holdings.

Number of Shares
128
Holding current value
$563
% of portfolio
0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 12, 2025

BUY
$3.3 - $5.42 $422 - $693
128 New
128 $0
Q4 2023

Dec 26, 2024

BUY
$2.48 - $4.39 $32 - $57
13 New
13 $0
Q4 2023

Feb 12, 2024

BUY
$2.48 - $4.39 $9 - $17
4 Added 44.44%
13 $0
Q3 2023

Nov 14, 2023

BUY
$3.41 - $5.51 $30 - $49
9 New
9 $0
Q3 2022

Nov 14, 2022

SELL
$4.59 - $6.5 $8,991 - $12,733
-1,959 Reduced 52.3%
1,787 $9,000
Q2 2022

Aug 11, 2022

SELL
$4.82 - $7.45 $20,591 - $31,826
-4,272 Reduced 53.28%
3,746 $21,000
Q1 2022

May 11, 2022

BUY
$5.6 - $8.22 $15,500 - $22,752
2,768 Added 52.72%
8,018 $57,000
Q4 2021

Feb 10, 2022

BUY
$7.11 - $11.04 $37,327 - $57,959
5,250 New
5,250 $42,000

Others Institutions Holding LTRN

About Lantern Pharma Inc.


  • Ticker LTRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 10,830,900
  • Market Cap $47.7M
  • Description
  • Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-30...
More about LTRN
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.